ASCO GU 2025

Combining ARPi with PARPi - discussing final OS of TALAPRO-2

Milestones of ADT and ARPI treatment in the metastastic prostate cancer

What's the role of Enzalutamide in radioligand therapy?

Phase 2 Mevrometostat

Who benefits most from ARPIs?

Testosterone Recovery

Testosterone Recovery after ADT and OS

Final OS analyses

Darolutamide + ADT reduces risk of progression or death by 46 % in mHSPC

ARPI for which patients?

Radical Prostatectomy VS RT in HRPC

Mevrometostat + Enza: New option for mCRPC

Radiation vs surgery in high risk prostate cancer

Improved Survival with Enzalutamide + Lutetium

MDT in OMPC

Fish-oil supplement for pts on active surveillance

Hypo-gonadism bad for survival?

Final OS data for TALA + Enza

Durvalumab in UTUC

Darolutamide + ADT and Doetaxel improves survivas in mHSPC across age groups

ENZA-p showed OS benefit and improvement in QoL parameters

OS in the TALAPRO-2 trial

Yuksek risk PCa da RP vs RT

Hangi hastalarda ADT+ARPI

Oligometastatik PCa da MDT

Testosteron Geri Gelisi ve Sagkalim

Enza+Lu ile artmis sagkalim

UTUC de Neoadj. Durvalumab+Kemo

Exciting new substances - but don't over-estimate phase 1 data

Triplet combination in RCC - there's no free lunch with VEGFR

New data but no new conclusion

KIM-1 - The most interesting biomarker for RCC?

Prognostic and predictive biomarkers in mRCC: Looking for the holy grail

Advanced Renal Cell Cancer: Adding more drugs does not translate in greater benefit

KIM-1 in CheckMate 214

AVION trial at mRCC

KIM-1 in mRCC

Casdatifan in refracting RCC

Biomarcadores prognósticos y predictivos en el CCRm: en busca del Santo Grial

Cáncer de células renales avanzado: añadir más fármacos no se traduce en un mayor beneficio

New data, but no new insights for adjuvant treatment of high-risk MIBC patients

Neoadjuvant chemo-immunotherapy in UTUC: new evidence for a challenging indication

Reassuring data on established ADCs and new insights in novel ADCs for urothelial cancer

ADC + ICI - The future for MIBC?

Exploratory analyses of pCR in NIAGARA: who benefits most from perioperative Durvalumab?

EV-Pembro continues to be the standard for mTCC

The role of ctDNA in bladder cancer

Neoadjuvant treatment for UTUC

Sacituzumab Tirumotecan shows promising antitumor activity in aUC after platinum-based therapy

ASCO GU 25 - Summary: Urothelial Cancer

New FGFR3 inhibitor

Durvalumab + Platinum-based chemotherapy shows promising efficacy and safety in high-grade UTUC

HER2 - new marker for bladder preservation

New drugs in mUC: The active field of ADCs

Nivo adjuvant in MIBC - a new standard

Phase 2 Mevrometastat

A possible new standard for mUC

Promising combination for perioperative setting

Adjuvant Nivo - independent from previous therapy

Bladder-sparing approaches - are we there yet?

Preliminary results of neoadjuvant chemoimmunotherapy in UTUC

Nuevos fármacos en mUC: El campo activo de las ADCs

ASCO GU 25 - Περίληψη: Ουροθηλιακός καρκίνος

Promising combination for perioperative setting

Testicular cancer: Reinventing the wheel

RPLND in metastatic Seminoma

Cáncer de testículo: reinventar la rueda

Metastatik seminomda Primer RPLND